Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft

Bibliography

• Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Rampudda M, Canova M, et al. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190-5
   PubMedGoogle Scholar
• Nowack R, Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965-71
   PubMed Web of Science ®Google Scholar
• Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-83
   PubMed Web of Science ®Google Scholar
• Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006;102:c100-7
   PubMedGoogle Scholar
• Jayne D, Amoura Z, Zeher M, et al. Enteric-coated mycophenolate sodium in patients with lupus nephritis: rationale and design of a multicenter randomized steroid-sparing trial. World Congress of Nephrology; Rio de Janeiro, Brazil; 21 - 25 April 2007 (Abstract 1114)
   Google Scholar
• Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004;5:1333-45
   PubMed Web of Science ®Google Scholar
• Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19:199-206
   PubMed Web of Science ®Google Scholar
• Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006;81:1290-7
   PubMed Web of Science ®Google Scholar
• Arns W, Gies M, Choi L, et al. Absorption characteristics of EC-MPS-an – enteric-coated formulation of mycophenolic sodium. Int J Clin Pharmacol Ther 2006;44:375-85
   PubMedGoogle Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58
   PubMed Web of Science ®Google Scholar
• Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007;7:888-98
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Cortinovis M, Baldelli S, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007;2:1147-55
   PubMedGoogle Scholar
• Budde K, Tedesco-Silva H, Pestana JM, et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monitor 2007;29:381-4
   PubMed Web of Science ®Google Scholar
• Czock D, Rasche FM, Carius A, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. J Clin Pharmacol 2007;47:850-9
   PubMedGoogle Scholar
• Shaw LM, Nawrocki A, Korecka M, et al. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monitor 2004;26:347-51
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005;78:317-321
   PubMed Web of Science ®Google Scholar
• Buchler M, Lebranchu Y, Beneton M, et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005;78:34-42
   PubMed Web of Science ®Google Scholar
• Smak Gregoor PJ, De Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999;68:1603-6
   PubMed Web of Science ®Google Scholar
• Neumann I, Haidinger M, Jäger H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared with renal transplant recipients. J Am Soc Nephrol 2003;14:721-7
   PubMed Web of Science ®Google Scholar
• Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
   PubMed Web of Science ®Google Scholar
• Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monitor 1998;20:685-90
   PubMed Web of Science ®Google Scholar
• Vogl M, Weigel G, Seebacher G, et al. Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring. Ther Drug Monitor 1999;21:638-43
   PubMedGoogle Scholar
• Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 2005;60:249-56
   PubMed Web of Science ®Google Scholar
• Westley IS, Brogan LR, Morris RG, et al. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 2006;34:261-6
   PubMed Web of Science ®Google Scholar
• Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997;5:225-32
   PubMed Web of Science ®Google Scholar
• Kaplan B, Meier-Kriesche HU, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005;19:551-8
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98
   PubMed Web of Science ®Google Scholar
• Van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant 2005;5:199-200
   PubMed Web of Science ®Google Scholar
• Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006;82:1004-12
   PubMed Web of Science ®Google Scholar
• Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin.2006;22:2355-64
   PubMed Web of Science ®Google Scholar
• Hummel M, Yonan N, Ross H, et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007;21:18-23
   PubMedGoogle Scholar
• Van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006;17:871-80
   PubMed Web of Science ®Google Scholar